Showing results (91-100 of 152) with videos related to
Sort By:
Pageof 16
The New England Journal of Medicine|October 12, 2017
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentEdward Gane, Eric Lawitz, David Pugatch, et al.Hepatology (Baltimore, Md.)|October 24, 2009
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonrespondersVinod K Rustgi, William M Lee, Eric Lawitz, et al.Hepatology (Baltimore, Md.)|October 12, 2007
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virusJohn G McHutchison, Bruce R Bacon, Stuart C Gordon, et al.Gastroenterology|March 8, 2014
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trialXavier Forns, Eric Lawitz, Stefan Zeuzem, et al.The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.Antiviral Research|June 11, 2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokineticsEric Lawitz, Mark Sulkowski, Ira Jacobson, et al.Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2019
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infectionEric Lawitz, Robert Flisiak, Manal Abunimeh, et al.Journal of Hepatology|October 25, 2023
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directionsVlad Ratziu, Marcus Hompesch, Mathieu Petitjean, et al.The New England Journal of Medicine|January 20, 2012
Preliminary study of two antiviral agents for hepatitis C genotype 1Anna S Lok, David F Gardiner, Eric Lawitz, et al.Hepatology Communications|February 7, 2018
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatmentEdward J Gane, Sophie Metivier, Ronald Nahass, et al.Pageof 16